# EDGAR Filing Document

**Accession Number:** 0001871321
**File Stem:** 0001213900-25-055181
**Filing Date:** 2025-6
**Character Count:** 5076
**Document Hash:** aafcb5d47ac87c27265d00546fb1731d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-055181.hdr.sgml**: 20250617

**ACCESSION NUMBER**: 0001213900-25-055181

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250617

**FILED AS OF DATE**: 20250617

**DATE AS OF CHANGE**: 20250617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Alpha Tau Medical Ltd.
- **CENTRAL INDEX KEY:** 0001871321
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41316
- **FILM NUMBER:** 251053316

**BUSINESS ADDRESS:**
- **STREET 1:** KIRYAT HAMADA 5
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 9777605
- **BUSINESS PHONE:** 972-3-577-4115

**MAIL ADDRESS:**
- **STREET 1:** KIRYAT HAMADA 5
- **CITY:** JERUSALEM
- **STATE:** L3
- **ZIP:** 9777605

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO SECTION 13A-16 OR 15D-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of June 2025**

**Commission File Number: 001-41316**

**Alpha Tau Medical Ltd.**

**(Exact Name of Registrant as Specified in Its Charter)**

**Kiryat HaMada St. 5**

**Jerusalem, Israel 9777605**

**+972 (3) 577-4115**

**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**CONTENTS**

On June 17, 2025, Alpha Tau Medical Ltd. (the "**Company**") held its Annual General Meeting of Shareholders (the "**Meeting**") at the Company's headquarters at 5 Kiryat Hamada St., Jerusalem 9777605, Israel.

At the Meeting, the Company's shareholders approved the following proposals:

(1) To re-elect each of Alan Adler and S. Morry Blumenfeld, and
to elect Nadav Kidron, as Class I directors, to hold office until the close of the Company's Annual General Meeting of Shareholders
in 2028, and until their respective successors are duly elected and qualified, or until their respective offices are vacated in accordance
with the Company's Amended and Restated Articles of Association or the Israeli Companies Law, 5759-1999 (the "**Companies Law** ");

(2) to approve the issuance of warrants to purchase 2,390,000
ordinary shares of the Company, no par value ()"**Shares**") each with an exercise price of $3.90 per share, and warrants
to purchase 847,000 Shares each with an exercise price of $3.474 per share, pursuant to the strategic services agreement by and between
the Company and Oramed Ltd. dated April 24, 2025;

(3) to approve the re-appointment of Kost, Forer, Gabbay &
Kasierer, registered public accounting firm, a member of Ernst & Young Global, as the Company's independent registered public
accounting firm for the year ending December 31, 2025 and until the Company's next annual general meeting of shareholders, and
to authorize the Company's board of directors (with power of delegation to its audit committee) to set the fees to be paid to such
auditors; and

(4) to approve and ratify an amendment to the Company's
Non-Employee Director Compensation Package.

All proposals were approved at the Meeting by the respective requisite majorities in accordance with the Companies Law, and the Company's Amended and Restated Articles of Association, as described in the Proxy Statement which was attached as Exhibit 99.1 to the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission on May 13, 2025.

This Form 6-K is incorporated by reference into the Company's registration statements on Form F-3 (File Nos. [333-271073](https://www.sec.gov/Archives/edgar/data/1871321/000121390023025885/ea176189-f3_alphatau.htm), [333-264306](https://www.sec.gov/Archives/edgar/data/1871321/000121390023025889/ea176120-posam_alphatau.htm) and [333-274457](https://www.sec.gov/Archives/edgar/data/1871321/000121390023075741/ea185018-f3_alphatau.htm)) and Form S-8 (File Nos. [333-264169](https://www.sec.gov/Archives/edgar/data/1871321/000110465922043414/tm229943d2_s8.htm)<u>,</u> [333-270406](https://www.sec.gov/Archives/edgar/data/1871321/000121390023018900/ea174831-s8_alphatau.htm), [333-277733](http://www.sec.gov/Archives/edgar/data/1871321/000121390024020783/ea0201210-s8_alphatau.htm) and [333-285745](http://www.sec.gov/Archives/edgar/data/1871321/000121390025023243/ea0233726-s8_alphatau.htm)).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Alpha Tau Medical Ltd.** | **Alpha Tau Medical Ltd.** |
| Date: June 17, 2025 | By: | /s/ Uzi Sofer |
|  |  | Uzi Sofer |
|  |  | Chief Executive Officer |

---